Skip to main content
. 2017 Jan 1;8(1):85–96. doi: 10.7150/jca.16792

Table 1.

Comparative analysis of the anticancer effects of human tissue-derived normal MSCs in vitro and in vivo.

Type of MSCs Tumor propagating effect Tumor inhibiting effect
Bone marrow Acute lymphoblastic leukemia Hepatocellular carcinoma
Acute myeoblastic leukemia Pancreatic cancer
Chronic lymphocytic leukemia Glioma
Lymphoma
Multiple myeloma
Breast cancer
Hepatocellular carcinoma
Colorectal cancer
Colon cancer
Prostate cancer
Renal cell carcinoma
Endometrial tumors
Glioma
Osteosarcoma
Prostate cancer
Ovarian cancer
Gastric cancer
Pancreatic cancer
Lung cancer
Oral tongue tumor
Adipose tissues Acute lymphoblastic leukemia Murine T-cell lymphoma
Acute promyelocytic leukemia Multiple myeloma
Chronic lymphocytic leukemia Hepatic cancer
Breast cancer Colorectal adenocarcinoma
Lung cancer Prostate cancer
Ovarian cancer Glioma
Prostate cancer Melanoma
Kaposi sarcoma
Melanoma tumor
Colon cancer
Prostate cancer
Endometrial tumors
Glioma
Head/neck cancer
Umbilical cord/cord Blood Acute lymphoblastic leukemia Acute lymphoblastic leukemia
Acute myeoblastic leukemia Chronic myeloid leukemia in blast crisis
Breast cancer Acute myeoblastic leukemia
Gastric epithelial cell Burkitt's lymphoma
Esophageal cancer Multiple myeloma
Mouse pancreatic cancer Breast cancer
Ovarian cancer Hepatic cancer
Cholangiocarcinoma
Bronchioloalveolar carcinoma
Prostate cancer
Bladder tumor
Ovarian carcinoma
Glioma
Esophageal cancer
Lung cancer

Note: Distinct MSCs come from different origins and exhibit a diverse range of anticancer properties. The MSCs from bone marrow and adipose tissues mainly show tumor-propagating effects; however, MSCs from umbilical cord/cord blood mainly show tumor-inhibiting effects.